摘要
目的评价利奈唑胺治疗小儿重症肺炎的效果和对患者生活质量的影响。方法病例收集时间于2018年9月—2020年4月,从医院收治的重症肺炎患儿中抽选出88例作为主要观察对象,按照患儿入院时间顺序进行分组,对照组和观察组各44例,对照组患儿接受万古霉素治疗,观察组在对照组基础上联合利奈唑胺治疗,观察比较两组患儿的临床治疗效果、生活质量、炎症因子和症状改善情况。结果观察组患儿治疗后的临床总有效率(97.73%)明显高于对照组(81.82%),差异具有统计学意义(P<0.05);观察组患儿的各项生活质量评分结果均明显高于对照组,差异具有统计学意义(P<0.05);观察组患儿治疗后的各项炎症因子水平指标和临床各症状改善效果均显著优于对照组,差异具有统计学意义(P<0.05)。结论临床治疗小儿重症肺炎选择利奈唑胺的临床疗效确切,对改善其生活质量,减轻炎症水平具有积极作用。
Objective To evaluate the effect of linezolid in the treatment of severe pneumonia in children and its influence on the quality of life of the patients.Methods From September 2018 to April 2020,88 children with severe pneumonia in our hospital were selected as the main observation objects and divided into control group and observation group according to the order of admission time.The control group received vancomycin treatment,and the observation group received linezolid treatment on the basis of the control group Treatment effect,quality of life,inflammatory factors and symptom improvement.Results The clinical total effective rate of the observation group(97.73%)was significantly higher than that of the control group(81.82%),the statistical difference was significant(P<0.05);the scores of the quality of life of the observation group were significantly higher than those of the control group,and the statistical difference was significant(P<0.05);the levels of inflammatory factors and clinical symptoms of the observation group after treatment were significantly better than those of the control group In the control group,the difference was statistically significant(P<0.05).Conclusion Linezolid is effective in the treatment of severe pneumonia in children.It has a positive effect on improving the quality of life and reducing the level of inflammation.
作者
梁力泳
LIANG Liyong(The Second Department of Pediatrics,Qiqihar Hospital of Traditional Chinese Medicine,Qiqihar Heilongjiang 161000,China)
出处
《中国卫生标准管理》
2021年第18期84-87,共4页
China Health Standard Management
关键词
利奈唑胺
小儿
重症肺炎
临床疗效
生活质量
炎症因子指标
linezolid
children
severe pneumonia
clinical efficacy
quality of life
inflammatory factors